Eversept Partners
Latest statistics and disclosures from Eversept Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NTRA, QQQ, GSK, VERA, INSP, and represent 45.20% of Eversept Partners's stock portfolio.
- Added to shares of these 10 stocks: TLT (+$16M), HCA (+$14M), BRKR (+$14M), EW (+$13M), DXCM (+$12M), TFX (+$11M), BCRX (+$11M), PCVX (+$10M), PTGX (+$9.0M), GH (+$8.4M).
- Started 15 new stock positions in SUPN, TFX, XRAY, GH, PDCO, HSIC, XENE, EW, PCVX, MEDP. ITOS, DXCM, AZN, BRKR, TLT.
- Reduced shares in these 10 stocks: INSM (-$80M), SNDX (-$50M), UTHR (-$31M), TECH (-$26M), TEVA (-$22M), VERA (-$19M), CYH (-$18M), SPY (-$18M), RGEN (-$16M), GSK (-$13M).
- Sold out of its positions in AVTE, BHC, BKD, INSM, ITCI, IQV, KURA, MRVI, MOH, NVRO. FNA, STAA, STOK, TRML, BHVN, ACIU, AFMD.
- Eversept Partners was a net seller of stock by $-237M.
- Eversept Partners has $1.1B in assets under management (AUM), dropping by -22.84%.
- Central Index Key (CIK): 0001697013
Tip: Access up to 7 years of quarterly data
Positions held by Eversept Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Eversept Partners
Eversept Partners holds 65 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Natera (NTRA) | 12.3 | $139M | 877k | 158.30 |
|
|
| Invesco Qqq Tr Unit Ser 1 Put Option (QQQ) | 11.0 | $124M | -2% | 243k | 511.23 |
|
| GSK Sponsored Adr (GSK) | 11.0 | $124M | -9% | 3.7M | 33.82 |
|
| Vera Therapeutics Cl A (VERA) | 6.0 | $68M | -21% | 1.6M | 42.29 |
|
| Inspire Med Sys (INSP) | 4.8 | $55M | +6% | 294k | 185.38 |
|
| Hca Holdings (HCA) | 4.7 | $53M | +36% | 176k | 300.15 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 4.4 | $49M | -30% | 2.2M | 22.04 |
|
| PerkinElmer (RVTY) | 3.9 | $44M | -16% | 393k | 111.61 |
|
| Healthequity (HQY) | 3.3 | $37M | +21% | 387k | 95.95 |
|
| Zimvie (ZIMV) | 2.6 | $29M | 2.1M | 13.95 |
|
|
| Protagonist Therapeutics (PTGX) | 2.3 | $26M | +52% | 679k | 38.60 |
|
| Bio-techne Corporation (TECH) | 1.9 | $22M | -54% | 299k | 72.03 |
|
| Celldex Therapeutics Com New (CLDX) | 1.6 | $18M | +27% | 720k | 25.27 |
|
| Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY) | 1.6 | $18M | -50% | 30k | 586.08 |
|
| Viatris (VTRS) | 1.4 | $16M | -26% | 1.3M | 12.45 |
|
| Ishares Tr 20 Yr Tr Bd Etf Put Option (TLT) | 1.4 | $16M | NEW | 179k | 87.33 |
|
| United Therapeutics Corporation (UTHR) | 1.4 | $15M | -66% | 44k | 352.84 |
|
| Miragen Therapeutics (VRDN) | 1.3 | $15M | +12% | 780k | 19.17 |
|
| BioCryst Pharmaceuticals (BCRX) | 1.3 | $15M | +269% | 2.0M | 7.52 |
|
| Bruker Corporation (BRKR) | 1.2 | $14M | NEW | 235k | 58.62 |
|
| Edwards Lifesciences (EW) | 1.1 | $13M | NEW | 171k | 74.03 |
|
| Dex (DXCM) | 1.0 | $12M | NEW | 149k | 77.77 |
|
| Centene Corporation (CNC) | 1.0 | $11M | +39% | 189k | 60.58 |
|
| Teleflex Incorporated (TFX) | 1.0 | $11M | NEW | 62k | 177.98 |
|
| Anthem (ELV) | 1.0 | $11M | +49% | 29k | 368.90 |
|
| Vaxcyte (PCVX) | 0.9 | $10M | NEW | 128k | 81.86 |
|
| Travere Therapeutics (TVTX) | 0.8 | $8.5M | -43% | 490k | 17.42 |
|
| Community Health Systems (CYH) | 0.8 | $8.5M | -67% | 2.8M | 2.99 |
|
| Guardant Health (GH) | 0.7 | $8.4M | NEW | 276k | 30.55 |
|
| Repligen Corporation (RGEN) | 0.7 | $7.8M | -66% | 54k | 143.94 |
|
| Ionis Pharmaceuticals (IONS) | 0.7 | $7.5M | -54% | 215k | 34.96 |
|
| Fortrea Hldgs Common Stock (FTRE) | 0.7 | $7.5M | -12% | 402k | 18.65 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.6 | $7.1M | -10% | 275k | 25.70 |
|
| Astrazeneca Sponsored Adr (AZN) | 0.6 | $6.7M | NEW | 103k | 65.52 |
|
| Liquidia Corporation Com New (LQDA) | 0.6 | $6.7M | +314% | 571k | 11.76 |
|
| Medpace Hldgs (MEDP) | 0.6 | $6.3M | NEW | 19k | 332.23 |
|
| Xenon Pharmaceuticals (XENE) | 0.5 | $6.1M | NEW | 156k | 39.20 |
|
| Mannkind Corp Com New (MNKD) | 0.5 | $5.9M | -54% | 911k | 6.43 |
|
| Humana (HUM) | 0.5 | $5.8M | -33% | 23k | 253.71 |
|
| Henry Schein (HSIC) | 0.5 | $5.6M | NEW | 80k | 69.20 |
|
| Danaher Corporation (DHR) | 0.5 | $5.1M | -42% | 22k | 229.55 |
|
| Syndax Pharmaceuticals (SNDX) | 0.4 | $4.5M | -91% | 343k | 13.22 |
|
| Patterson Companies (PDCO) | 0.4 | $4.5M | NEW | 146k | 30.86 |
|
| Gossamer Bio (GOSS) | 0.4 | $4.5M | 5.0M | 0.90 |
|
|
| Evolus (EOLS) | 0.4 | $4.2M | -15% | 383k | 11.04 |
|
| Icon SHS (ICLR) | 0.4 | $4.0M | +40% | 19k | 209.71 |
|
| Supernus Pharmaceuticals (SUPN) | 0.3 | $3.8M | NEW | 106k | 36.16 |
|
| Avantor (AVTR) | 0.3 | $3.5M | 168k | 21.07 |
|
|
| Puma Biotechnology (PBYI) | 0.3 | $3.0M | -22% | 996k | 3.05 |
|
| 2seventy Bio Common Stock (TSVT) | 0.3 | $3.0M | 1.0M | 2.94 |
|
|
| Merus N V (MRUS) | 0.3 | $2.9M | 68k | 42.05 |
|
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.2 | $2.7M | 778k | 3.50 |
|
|
| Zai Lab Adr (ZLAB) | 0.2 | $2.7M | -23% | 103k | 26.19 |
|
| Arcutis Biotherapeutics (ARQT) | 0.2 | $2.7M | -72% | 191k | 13.93 |
|
| Dentsply Sirona (XRAY) | 0.2 | $2.7M | NEW | 140k | 18.98 |
|
| Xoma Royalty Corporation Com New (XOMA) | 0.2 | $2.5M | 95k | 26.28 |
|
|
| Iteos Therapeutics (ITOS) | 0.2 | $1.7M | NEW | 220k | 7.68 |
|
| Karyopharm Therapeutics (KPTI) | 0.1 | $1.4M | -62% | 2.1M | 0.68 |
|
| Zenas Biopharma (ZBIO) | 0.1 | $1.4M | -9% | 172k | 8.19 |
|
| Sutro Biopharma (STRO) | 0.1 | $1.3M | -62% | 694k | 1.84 |
|
| Inflarx Nv (IFRX) | 0.1 | $1.2M | -69% | 493k | 2.47 |
|
| Amarin Corp Spons Adr New (AMRN) | 0.1 | $736k | -54% | 1.5M | 0.48 |
|
| Absci Corp (ABSI) | 0.0 | $523k | -26% | 200k | 2.62 |
|
| Alector (ALEC) | 0.0 | $378k | -39% | 200k | 1.89 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.0 | $232k | -75% | 99k | 2.35 |
|
Past Filings by Eversept Partners
SEC 13F filings are viewable for Eversept Partners going back to 2017
- Eversept Partners 2024 Q4 filed Feb. 14, 2025
- Eversept Partners 2024 Q3 filed Nov. 14, 2024
- Eversept Partners 2024 Q2 filed Aug. 14, 2024
- Eversept Partners 2024 Q1 filed May 15, 2024
- Eversept Partners 2023 Q4 filed Feb. 14, 2024
- Eversept Partners 2023 Q3 filed Nov. 14, 2023
- Eversept Partners 2017 Q4 restated filed Nov. 8, 2023
- Eversept Partners 2018 Q1 restated filed Nov. 8, 2023
- Eversept Partners 2018 Q2 restated filed Nov. 8, 2023
- Eversept Partners 2018 Q3 restated filed Nov. 8, 2023
- Eversept Partners 2018 Q4 restated filed Nov. 8, 2023
- Eversept Partners 2019 Q1 restated filed Nov. 8, 2023
- Eversept Partners 2019 Q2 restated filed Nov. 8, 2023
- Eversept Partners 2019 Q3 restated filed Nov. 8, 2023
- Eversept Partners 2019 Q4 restated filed Nov. 8, 2023
- Eversept Partners 2020 Q1 restated filed Nov. 8, 2023